Anzeige
Mehr »
Login
Dienstag, 06.06.2023 Börsentäglich über 12.000 News von 690 internationalen Medien
NuGen Medical: 8,4 Mio. CAD Umsatz von einem einzelnen Kunden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N9D9 | ISIN: US60770K1079 | Ticker-Symbol: 0QF
Xetra
06.06.23
16:57 Uhr
118,34 Euro
-4,26
-3,47 %
1-Jahres-Chart
MODERNA INC Chart 1 Jahr
5-Tage-Chart
MODERNA INC 5-Tage-Chart
RealtimeGeldBriefZeit
119,06119,2817:13
119,04119,3017:13

Aktuelle News zur MODERNA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17:10Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Spreading2
09:59ASCO: Moderna, Merck melanoma vaccine set for phase 316
03:46Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data19
MoLooking At Moderna's Recent Unusual Options Activity9
MoModerna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%7
MODERNA Aktie jetzt für 0€ handeln
MoModerna cancer vaccine used with Merck Keytruda reduces risk of deadly skin cancer spreading15
MoModerna/ Merck cancer shot with Keytruda cut melanoma spread7
MoModerna-Merck mRNA vaccine reduces cancer metastases by 65% in PhII melanoma study: ASCO2311
MoModerna, Inc.: Moderna and Merck Announce mRNA-4157 in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma412mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA aloneThe DMFS results...
► Artikel lesen
MoTaiwan: Academia Sinica and Moderna to cooperate on mRNA research10
FrBetter Healthcare AI Stock: Moderna vs. Doximity20
FrAcademia, Moderna to work on mRNA research9
DoModerna, Inc.: Moderna to Present at Upcoming Conferences in June 2023369CAMBRIDGE, MA / ACCESSWIRE / June 1, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following...
► Artikel lesen
DoCOVID Concerns Are Rising in China Again: Will This Send Moderna's Stock Soaring?16
30.05.Alnylam files new round of lawsuits against Moderna and Pfizer over Covid-19 vaccines11
30.05.Looking At Moderna's Recent Unusual Options Activity13
30.05.Alnylam sticks with aggressive litigation strategy against Pfizer and Moderna, filing yet another patent lawsuit11
30.05.Moderna, Inc.: Moderna Announces Phase 2 Data on mRNA-4157 , an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting397ASCO presentations on Saturday, June 3 at 4:30pm CDT and Monday, June 5 at 3:00pm CDTModerna to host investor event via webcast on Monday, June 5 at 6pm CDTCAMBRIDGE, MA / ACCESSWIRE / May 30, 2023...
► Artikel lesen
30.05.If You Invested $2,500 in Moderna in 2019, This Is How Much You Would Have Today8
27.05.Alnylam klagt Moderna und Pfizer wegen Patentverletzung59
Seite:  Weiter >>
1.064 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
12,8,35